Year in review 2009: Critical Care - shock

Critical Care

Volumn 14, Issue 6, 2010, Pages

  Stahl, Wolfgang ^a   Bracht, Hendrik ^a   Radermacher, Peter ^a   Thomas, Jörg ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CALCIUM ION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; CALCIUM HOMEOSTASIS; CYTOKINE PRODUCTION; ECHOCARDIOGRAPHY; FLUID RESUSCITATION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMICS; HUMAN; INTENSIVE CARE; MEDULLA OBLONGATA; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; THORAX EPIDURAL ANESTHESIA; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; CLINICAL TRIAL (TOPIC); FLUID THERAPY; METHODOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; FLUID THERAPY; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SHOCK;

EID: 78650509049     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9261     Document Type: Review

References (86)

1. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in septic shock. Curr Opin Crit Care 2009, 15:392-397. 10.1097/MCC.0b013e3283307a4e, 19633546.
2. Hunter JD, Doddi M. Sepsis and the heart. Br J Anaesth 2010, 104:3-11. 10.1093/bja/aep339, 19939836.
3. Joulin O, Marechaux S, Hssoun S, Montaigne D, Lancel S, Neviere R. Cardiac force-frequency relationship and frequency-dependent acceleration are impaired in LPS-treated rats. Crit Care 2009, 13:R14. 2688131, 19196490, 10.1186/cc7712.
4. Heitner SB, Hollenberg SM. The cardiac force-frequency relationship and frequency-dependent acceleration of relaxation are impaired in lipopolysaccharide-treated rats: is the phospholamban-SERCA axis a therapeutic target?. Crit Care 2009, 13:132. 2689476, 19439042, 10.1186/cc7752.
5. Barth E, Radermacher P, Thiemermann C, Weber S, Georgieff M, Albuszies G. Role of iNOS in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med 2006, 34:307-313. 10.1097/01.CCM.0000199070.46812.21, 16424707.
6. Bougaki M, Searles RJ, Kida K, De Yu J, Buys ES, Ichinose F. NOS3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis. Shock 2010, 34:281-290. 10.1097/SHK.0b013e3181cdc327, 19997049.
7. Zausig YA, Busse H, Lunz D, Sinner B, Zink W, Graf BM. Cardiac effects of induction agents in the septic rat heart. Crit Care 2009, 13:R144. 2784361, 19737388, 10.1186/cc8038.
8. Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35:1868-1876. 10.1007/s00134-009-1603-4, 19652948.
9. Royse CF. Anaesthesia in septic patients: good preparation and making the right choice?. Crit Care 2009, 13:1001. 10.1186/cc8133, 19895717, 2811922.
10. Zausig YA, Geilfus D, Missler G, Sinner B, Graf BM, Zink W. Direct cardiac effects of dobutamine, dopamine, epinephrine, and levosimendan in isolated septic rat hearts. Shock 2010, 34:269-274. 10.1097/SHK.0b013e3181cd877b, 19997056.
11. Flierl MA, Rittirsch D, Huber-Lang M, Sarma JV, Ward PA. Catecholamines - crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora's box?. Mol Med 2008, 14:195-204. 2136428, 18079995.
12. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296. 1783813, 17273548, 10.1172/JCI30555.
13. Hofer S, Eisenbach C, Lukic IK, Schneider L, Bode K, Mautner S, Wente MN, Encke J, Werner J, Dalpke AH, Nawroth PP, Martin E, Krammer PH, Bierhaus A, Weigand MA. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med 2008, 36:404-408. 10.1097/01.CCM.0B013E31816208B3, 18091537.
14. Hofer S, Steppan J, Wagner T, Funke B, Lichtenstern C, Martin E, Graf BM, Bierhaus A, Weigand MA. Central sympatholytics prolong survival in experimantal sepsis. Crit Care 2009, 13:R11. 2688128, 19196475, 10.1186/cc7709.
15. Ulloa L, Deitch EA. Neuroimmune perspectives in sepsis. Crit Care 2009, 13:133. 2689482, 19439052, 10.1186/cc7758.
16. Lauer S, Freise H, Westphal M, Zarbock A, Fobker M, Van Aken H, Sielenkämper AW, Fischer LG. Thoracic epidural anesthesia time-dependently modulates pulmonary endothelial dysfunction in septic rats. Crit Care 2009, 13:R109. 2750151, 19580652, 10.1186/cc7950.
17. Freise H, Daudel F, Grosserichter C, Lauer S, Hinkelmann J, Van Aken H, Sielenkämper AW, Westphal M, Fischer LG. Thoracic epidural anesthesia reverses sepsis-induced hepatic hyperperfusion and reduces leukocyte adhesion in septic rats. Crit Care 2009, 13:R116. 2750163, 19594914, 10.1186/cc7965.
18. Freise H, Lauer S, Anthonsen S, Hlouschek V, Minin E, Fischer LG, Lerch MM, Van Aken HK, Sielenkämper AW. Thoracic epidural analgesia augments ileal mucosal capillary perfusion and improves survival in severe acute pancreatitis in rats. Anesthesiology 2006, 105:354-359. 10.1097/00000542-200608000-00019, 16871070.
19. Lauer S, Freise H, Fischer LG, Singbartl K, Aken HV, Lerch MM, Sielenkämper AW. The role of thoracic epidural analgesia in receptor-dependent and receptor-independent pulmonary vasoconstriction in experimental pancreatitis. Anesth Analg 2007, 105:453-459. 10.1213/01.ane.0000268492.02554.17, 17646505.
20. Daudel F, Bone HG, Traber DL, Stubbe HD, Lettau M, Lange M, Scharte M, Van Aken H, Westphal M. Effects of thoracic epidural anesthesia on hemodynamics and global oxygen transport in ovine endotoxemia. Shock 2006, 26:615-619. 10.1097/01.shk.0000228799.25797.fb, 17117138.
21. Sielenkämper AW, Van Aken H. Epidural analgesia in sepsis: too early to judge a new concept. Intensive Care Med 2004, 30:1987-1989. 10.1007/s00134-004-2447-6, 15448890.
22. Adolphs J, Schmidt DK, Korsukewitz I, Kamin B, Habazettl H, Schäfer M, Welte M. Effects of thoracic epidural anaesthesia on intestinal microvascular perfusion in a rodent model of normotensive endotoxaemia. Intensive Care Med 2004, 30:2094-2101. 10.1007/s00134-004-2426-y, 15338125.
23. Schäper J, Ahmed R, Perschel FH, Schäfer M, Habazettl H, Welte M. Thoracic epidural anesthesia attenuates endotoxin-induced impairment of gastrointestinal organ perfusion. Anesthesiology 2010, 113:126-133. 10.1097/ALN.0b013e3181de0fdd, 20526186.
24. Spackman DR, McLeod AD, Prineas SN, Leach RM, Reynolds F. Effect of epidural blockade on indicators of splanchnic perfusion and gut function in critically ill patients with peritonitis: a randomised comparison of epidural bupivacaine with systemic morphine. Intensive Care Med 2000, 26:1638-1645. 10.1007/s001340000671, 11193270.
25. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265.
26. Choong K, Bohn D, Fraser DD, Gaboury I, Hutchison JS, Joffe AR, Litalien C, Menon K, McNamara P, Ward RE, . Canadian Critical Care Trials Group Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med 2009, 180:632-639. 10.1164/rccm.200902-0221OC, 19608718, Canadian Critical Care Trials Group.
27. Collier B, Dossett L, Mann M, Cotton B, Guillamondegui O, Diaz J, Fleming S, May A, Morris J. Vasopressin use is associated with death in acute trauma patients with shock. J Crit Care 2010, 25:173.e9-14.
28. Mayr VD, Luckner G, Jochberger S, Wenzel V, Hasibeder WR, Dünser MW. Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states. Anaesthesist 2007, 56:1017-1023. 10.1007/s00101-007-1227-4, 17594065.
29. Idrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR. Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care 2009, 13:R98. 2717470, 19549333, 10.1186/cc7930.
30. Asfar P, Radermacher P. Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?. Crit Care 2009, 13:169. 2750154, 19664189, 10.1186/cc7954.
31. Müller S, How OJ, Hermansen SE, Stenberg TA, Sager G, Myrmel T. Vasopressin impairs brain, heart and kidney perfusion. An experimental study in pigs after transient myocardial ischemia. Crit Care 2008, 12:R20. 2374634, 18291025, 10.1186/cc6794.
32. Wilson MF, Brackett DJ, Archer LT, Hinshaw LB. Mechanisms of impaired cardiac function by vasopressin. Ann Surg 1980, 191:494-500. 1344573, 7369815, 10.1097/00000658-198004000-00017.
33. Weig HJ, Laugwitz KL, Moretti A, Kronsbein K, Städele C, Brüning S, Seyfarth M, Brill T, Schömig A, Ungerer M. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 2000, 101:1578-1585.
34. Ryckwaert F, Virsolvy A, Fort A, Murat B, Richard S, Guillon G, Colson PH. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009, 37:876-881. 10.1097/CCM.0b013e31819b8199, 19237891.
35. Simon F, Giudici R, Scheuerle A, Gröger M, Asfar P, Vogt JA, Wachter U, Ploner F, Georgieff M, Möller P, Laporte R, Radermacher P, Calzia E, Hauser B. Comparison of cardiac, hepatic and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized, controlled trial. Crit Care 2009, 13:R113. 2750159, 19591694, 10.1186/cc7959.
36. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hébert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010, 36:83-91. 10.1007/s00134-009-1687-x, 19841897.
37. Nygren A, Thorén A, Ricksten SE. Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 2009, 53:581-588. 10.1111/j.1399-6576.2008.01900.x, 19239407.
38. Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE. Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anaesthesiol Scand 2009, 53:1052-1059. 10.1111/j.1399-6576.2009.02037.x, 19572935.
39. Dünser MW, Westphal M. Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond. Curr Opin Anaesthesiol 2008, 21:122-127. 18443477, 10.1097/ACO.0b013e3282f4571a.
40. Morelli A, Ertmer C, Rehberg S, Lnage M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009, 13:R130. 2750187, 19664253, 10.1186/cc7990.
41. Leone M. Terlipressin or Europressin?. Crit Care 2009, 13:192. 2784359, 19832999, 10.1186/cc8035.
42. Rehberg S, Enkhbaatar P, Traber DL. Arginine vasopressin in septic shock: supplement or substitute for norepinephrine?. Crit Care 2009, 13:178. 2750182, 19691818, 10.1186/cc7985.
43. Rehberg S, Ertmer C, Köhler G, Spiegel HU, Morelli A, Lange M, Moll K, Schlack K, Van Aken H, Su F, Vincent JL, Westphal M. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009, 35:1286-1296. 10.1007/s00134-009-1470-z, 19360396.
44. Schrier RW. Fluid administration in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2010, 5:733-739. 10.2215/CJN.00060110, 20167687.
45. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958.
46. Schortgen F, Girou E, Deye N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008, 34:2157-2168. 10.1007/s00134-008-1225-2, 18685828.
47. Boldt J. Pro: Hydroxyethylstarch can be safely used in the intensive care patient - the renal debate. Intensive Care Med 2009, 35:1331-1336. 10.1007/s00134-009-1520-6, 19533094.
48. Hartog C, Reinhart K. Contra: Hydroxyethyl starch solutions are unsafe in critically ill patients. Intensive Care Med 2009, 35:1337-1342. 10.1007/s00134-009-1521-5, 19533093.
49. Boldt J, Suttner S, Brosch C, Lehmann A, Röhm K, Mengistu A. The influence of a balanced volume replacement concept on inflammation, endothelial activation, and kidney integrity in elderly cardiac surgery patients. Intensive Care Med 2009, 35:462-470. 10.1007/s00134-008-1287-1, 18807007.
50. Schabinski F, Oishi J, Tuche F, Luy A, Sakr Y, Bredle D, Hartog C, Reinhart K. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med 2009, 35:1539-1547. 10.1007/s00134-009-1509-1, 19533095.
51. Hüter L, Simon TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, Amann KU, Marx G. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009, 13:R23. 2688141, 19239718, 10.1186/cc7726.
52. Schick MA, Isbary TJ, Schlegel N, Brugger J, Waschke J, Muellenbach R, Roewer N, Wunder C. The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 2010, 36:541-548. 10.1007/s00134-009-1704-0, 19890625.
53. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008, 8:1. 2245977, 18218122, 10.1186/1471-227X-8-1.
54. Schortgen F, Brochard L. Colloid-induced kidney injury: experimental evidence may help to understand mechanisms. Crit Care 2009, 13:130. 2689470, 19435473, 10.1186/cc7745.
55. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007, 4:CD000567.
56. Hiltebrand LB, Kimberger O, Arnberger M, Brandt S, Kurz A, Sigurdsson GH. Crystalloids versus colloids for goal-directed fluid therapy in major surgery. Crit Care 2009, 13:R40. 2689484, 19302713, 10.1186/cc7761.
57. Brandt S, Regueira T, Bracht H, Porta F, Djafarzadeh S, Takala J, Gorrasi J, Borotto E, Krejci V, Hiltebrand LB, Bruegger LE, Beldi G, Wilkens L, Lepper PM, Kessler U, Jakob SM. Effect of fluid resuscitation on mortality and organ function in experimental sepsis models. Crit Care 2009, 13:R186. 2811934, 19930656, 10.1186/cc8179.
58. Phillips CR, Vinecore K, Hagg DS, Sawai RS, Differding JA, Watters JM, Schreiber MA. Resuscitation of haemorrhagic shock with normal saline vs. lactated Ringer's: effects on oxygenation, extravascular lung water and haemodynamics. Crit Care 2009, 13:R30. 2689461, 19257901, 10.1186/cc7736.
59. van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld ABJ. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med 2009, 37:1275-1281. 10.1097/CCM.0b013e31819cedfd, 19242338.
60. Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: β2-agonists and the acute respiratory distress syndrome. Crit Care 2004, 8:25-32. 420065, 14975042, 10.1186/cc2417.
61. Perkins GD, McAuley DF, Thickett DR, Gao F. The β-Agonist Lung Injury Trial (BALTI). A randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173:281-287. 10.1164/rccm.200508-1302OC, 16254268.
62. O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009, 37:2242-2249. 10.1097/CCM.0b013e3181a5506c, 19487934.
63. McAuley DF, Matthay MA. A role for β2 agonists in ARDS - the question remains unanswered. J Intensive Care Soc 2009, 10:172-173.
64. Briot R, Bayat S, Anglade D, Martiel JL sGrimbert F. Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs. Crit Care 2009, 13:R166. 2784397, 19845949, 10.1186/cc8137.
65. Schreiber T, Hueter L, Gaser E, Schmidt B, Karzai W. Effects of a catecholamine-induced increase in cardiac output on lung injury after experimental unilateral pulmonary acid instillation. Crit Care Med 2007, 35:1741-1748. 10.1097/01.CCM.0000269374.85160.BF, 17522573.
66. Lee JW. β2 adrenergic agonists in acute lung injury? The heart of the matter. Crit Care 2009, 13:1011. 10.1186/cc8171, 20017898.
67. Wang Z, Su F, Rogiers P, Vincent JL. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007, 35:2594-2600. 10.1097/01.CCM.0000287590.55294.40, 17901839.
68. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebretsen OC, Ytrehus K, Bjertnaes LJ. Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 2008, 12:R104. 2575593, 18702832, 10.1186/cc6985.
69. Waerhaug K, Kirov MY, Kuzkov VV, Kuklin VN, Bjertnaes LJ. Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep. Crit Care 2008, 12:R146. 2646309, 19021914, 10.1186/cc7128.
70. Richard JC, Bregeon F, Leray V, Le Bars D, Costes N, Tourvieille C, Lavenne F, Devouassoux-Shisheboran M, Gimenez G, Guerin C. Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury. Intensive Care Med 2007, 33:2199-2206. 10.1007/s00134-007-0782-0, 17671779.
71. Maybauer MO, Maybaier DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K, Mizutani A, Herndon DN, Traber DL. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 2006, 34:2432-2438. 10.1097/01.CCM.0000230384.61350.FA, 16810106.
72. Sennoun N, Meziani F, Dessebe O, Cattan V, Collin S, Montemont C, Gibot S, Asfar P, Ramaroson A, Regnault V, Slama M, Lecompte T, Lacolley P, Levy B. Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 2009, 37:246-255. 10.1097/CCM.0b013e318192fe4f, 19112282.
73. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008, 178:618-623. 2542435, 18565951, 10.1164/rccm.200803-419OC.
74. Waerhaug K, Kuzkov VV, Kuklin VN, Mortensen R, Nordhus KC, Kirov MY, Bjertnaes LJ. Inhaled aerosolised recombinant human activated protein C ameliorates endotoxin-induced lung injury in anaesthetised sheep. Crit Care 2009, 13:R51. 2689497, 19356243, 10.1186/cc7777.
75. Finigan JH, Boueiz A, Wilkinson E, Damico R, Skirball J, Pae HH, Damarla M, Hasan E, Pearse DB, Reddy SP, Grigoryev DN, Cheadle C, Esmon CT, Garcia JG, Hassoun PM. Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol 2009, 296:L1002-L1011. 2692806, 19363121, 10.1152/ajplung.90555.2008.
76. Maniatis NA, Letsiou E, Orfanos SE, Kardara M, Dimopoulou I, Nakos G, Lekka ME, Roussos C, Armaganidis A, Kotanidou A. Inhaled activated protein C protects mice from ventilator-induced lung injury. Crit Care 2010, 14:R70. 2887192, 20403177, 10.1186/cc8976.
77. Liu KD, Looney MR, Matthay MA. Inhaled activated protein C: a novel therapy for acute lung injury?. Crit Care 2009, 13:150. 2717421, 19519935, 10.1186/cc7869.
78. Skrupky LP, Micek ST, Kollef MH. Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. Crit Care 2009, 13:222. 2784352, 19889197, 10.1186/cc8028.
79. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006, 10:R97. 1550967, 16808853, 10.1186/cc4946.
80. Enkhbaatar P, Joncam C, Traber L, Nakano Y, Wang J, Lange M, Connelly R, Kulp G, Saunders F, Huda R, Cox R, Schmalstieg F, Herndon D, Traber D. Novel ovine model of methicillin-resistant Staphylococcus aureus-induced pneumonia and sepsis. Shock 2008, 29:642-649.
81. Jonkam CC, Lange M, Traber DL, Maybauer DM, Maybauer MO, Bansal K, Hamahata A, Zhu Y, Esechie A, Traber LD, Sousse L, Rehberg S, Herndon DN, Enkhbaatar P. Cardiovascular collapse and vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis. Shock 2009, 32:621-625. 10.1097/SHK.0b013e3181a4fd01, 19295474.
82. Rehberg S, Maybauer MO, Maybauer DM, Traber LD, Enkhbaatar P, Traber DL. The role of nitric oxide and reactive nitrogen species in experimental ARDS. Front Biosci (Schol Ed) 2010, 2:18-29. 20036926, 10.2741/s43.
83. Jonkam CC, Bansal K, Traber DL, Hamahata A, Maybauer MO, Maybauer DM, Cox RA, Lange M, Connelly RL, Traber LD, Djukom CD, Salsbury JR, Herndon DN, Enkhbaatar P. Pulmonary vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis. Crit Care 2009, 13:R19. 2688137, 19222851, 10.1186/cc7720.
84. Su F, Hunag H, Kazuki A, Occhipinti G, Donadello K, Piagnerelli M, De Backer D, Vincent JL. Effects of a selective iNOS inhibitor versus norepinephrine in the treatment of septic shock. Shock 2010, 34:243-249. 10.1097/SHK.0b013e3181d75967, 20160666.
85. Hollenberg SM, Cinel I. Bench-to-bedside review: Nitric oxide in critical illness - update 2008. Crit Care 2009, 13:218. 2750127, 19664175, 10.1186/cc7706.
86. Stahl W, Matejovic M, Radermacher P. Inhibition of nitric oxide synthase during sepsis: revival due to isoform selectivity?. Shock 2010, 34:321-322. 10.1097/SHK.0b013e3181d758b5, 20601934.